Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
65
resultados
Última actualización
01/04/2026 [08:42:00]
Resumen de: WO2025018933A1
The present embodiments relate to an immunoassay kit capable of measuring p-tau205 in a sample and to methods involving the use of such an immunoassay kit. The present embodiment also relates to a monoclonal antibody, or an antigen-binding fragment thereof, binding specifically to p-tau205 and that can be used in such an immunoassay kit.
Resumen de: WO2026064441A1
The disclosure is related to methods of treating a subject with Alzheimer's Disease (AD) using anti-amyloid beta (Aβ) therapy. The patient may be treated based on the measurement and analysis of biomarker levels, such as plasma Aβ42/40 ratio, pTau181 and pTau217. The disclosure includes a systematic approach called CP Convert for converting biomarker measurements across different analytical platforms, enabling comparison of pTau217 data from LC-MS/MS, SIMOA, and chemiluminescent enzyme immunoassay platforms. Methods demonstrate that pTau217 has superior diagnostic accuracy compared to Aβ42/40 ratio and pTau181 for detecting brain amyloid positivity. Implementation of pTau217 prescreening can significantly reduce Aβ-PET testing, decreasing patient burden and clinical trial costs. The CP Convert methodology can be validated using independent cohorts, demonstrating robust cross-platform conversion for research applications.
Resumen de: US20260083826A1
The present invention aims to provide a novel agent for treating Alzheimer's disease, a method for treating Alzheimer's disease, a method for screening for a candidate substance for a therapeutic drug for Alzheimer's disease, and the like. The present invention is a prophylactic and/or therapeutic agent for Alzheimer's disease comprising a peptide corresponding to dynamin 1. The peptide preferably corresponds to dynamin 1-pleckstrin-homology domain or dynamin 1-proline rich domain. In addition, the peptide is preferably encapsulated in nano-particles or linked to a peptide sequence that improve delivery of the peptide into the brain.
Resumen de: CN121152975A
The present invention relates to the use of biomarkers for measuring the efficacy or effectiveness of a treatment for neurodegenerative diseases, in particular Alzheimer's disease.
Resumen de: AU2024277300A1
The present invention relates to compositions and methods for promoting the removal of misfolded proteins and protein aggregates. The compositions and methods may be used to treat or prevent a neurodegenerative disease or disorder associated with misfolded proteins or protein aggregates. In various embodiments, the compositions and methods relate to activators of one or more TRIM proteins.
Resumen de: WO2024235880A1
The invention relates to an in vitro method for diagnosing or predicting a neurodegenerative disease in a subject, said method comprising A/T/N classification in nasal secretion samples obtained from said subject. Said A/T/N classification subsequently may be used, but is not limited to, the diagnosis of Alzheimer's disease (AD), the diagnosis of SNAP or the exclusion of AD.
Resumen de: AU2026201500A1
Abstract Methods and compositions for preventing or treating cognitive decline associated with dementia and/or mild cognitive impairment and/or neurodegeneration using antibodies, peptides, fusion proteins, or genome editing systems that modulate HSPG/heparin binding affinities of ApoE.
Resumen de: US20260008840A1
Provided herein are compositions and methods relating to improved assays for establishing a condition of a neurodegenerative disease and providing treatment. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays used for diagnosing Alzheimer's disease and providing treatment.
Resumen de: CN121399472A
The present invention relates to a nasal fluid sample obtained from a subject, the nasal fluid sample comprising one or more marker protein amyloid beta (A beta), phosphorylated Tau (pTau) and/or total Tau (tTau). The invention further relates to a nasal fluid sample comprising one or more marker proteins A beta, pTau and/or tTau for use in a method for aiding in the diagnosis of a degenerative disease of the nervous system, and to the use of a nasal fluid sample comprising one or more marker proteins A beta, pTau and/or tTau for aiding in the diagnosis of a degenerative disease of the nervous system. The invention further relates to a method for aiding the diagnosis of a nervous system degenerative disease in a subject/individual.
Resumen de: WO2024235880A1
The invention relates to an in vitro method for diagnosing or predicting a neurodegenerative disease in a subject, said method comprising A/T/N classification in nasal secretion samples obtained from said subject. Said A/T/N classification subsequently may be used, but is not limited to, the diagnosis of Alzheimer's disease (AD), the diagnosis of SNAP or the exclusion of AD.
Resumen de: MX2022001817A
The methods disclosed herein employ unique combinations of processing steps that transform a blood or CSF sample into a sample suitable for quantifying MTBR tau species, as well as other tau species. The present disclosure also encompasses the use of MTBR tau species in blood or CSF to measure pathological features and/or clinical symptoms of 3R- and 4R- tauopathies in order to diagnose, stage, and/or choose treatments appropriate for a given disease stage, and modify a given treatment regimen.
Resumen de: US20260072040A1
The invention relates to methods and uses of cell free histone H3 isoforms H3.1, H13.2, H3t and/or H3.3 (or cell free nucleosomes containing said isoforms) of determining the origin of a cell free histone or cell free nucleosome in a body fluid sample as originating from a dividing or non-dividing cell.
Resumen de: WO2026055173A1
The present invention provides a method for identifying a subject having a stabilized circulating peptide. The method comprises detecting the stabilized circulating peptide in a body fluid sample, for example, a serum or plasma sample, from the subject. The method may further comprise treating a neurodegenerative disease, or monitoring or adjusting a treatment of a neurodegenerative disease. Also provided is a kit. The kit comprises a binding protein that specifically binds a stabilized circulating peptide in a body fluid sample, for example, a serum or plasma sample, from a subject. The kit may further comprise an agent for detecting, treating or monitoring a neurodegenerative disease in the subject. The neurodegenerative disease may be Alzheimer disease.
Resumen de: WO2026051874A1
Provided are diagnostic and treatment methods,based on plasma protein markers for neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's Disease (AD),as well as kits for diagnosing and/or treating these condition.Machine learning systems and methods for assessing the risk for a subject having a neurodegenerative disease based on measured protein marker levels are also provided.
Resumen de: US20260072043A1
The present disclosure provides methods for diagnosing or determining susceptibility to Alzheimer's Disease a subject by obtaining a biological sample from the subject; detecting one or more biomarkers in the biological sample selected from the group consisting of: inflammation biomarkers, oxidative stress biomarkers, insulin resistance biomarkers, and autophagy biomarkers; and diagnosing the subject with Alzheimer's Disease where one or more of the biomarkers is detected in the biological sample. Also provided are methods of treating a subject with Alzheimer's Disease comprising administering to the subject an effective amount of one or more agents for the treatment of inflammation, oxidative stress, insulin resistance, and/or autophagy.
Resumen de: AU2024366503A1
Methods, kits and compositions of detecting analytes, typically analytes relevant to neurodegenerative diseases such as neurofilament light chain, in a sample are described herein using chemiluminescent labels. Solid supports, reagents, and compounds for use in these methods are also described. Typically, the methods involve specific assay formats which provide the requisite high resolution for detecting low concentrations of analytes in samples and may be used in positions of the healthcare ecosystem close to the patient. These methods, systems, and apparatuses may afford early detection and prognosis of a wide variety of neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis.
Resumen de: CN121039498A
The present invention relates to a method for the in vitro diagnosis of a neurodegenerative disease in a human or animal individual in the early stage, comprising a step comprising the detection of the presence of at least one marker selected from the group consisting of derived forms of amyloid beta (A beta) peptides, the derivative forms are selected from oligomers of the peptide and pre-fibrotic and fibrotic aggregated forms of the peptide, and derivative forms of a phosphorylated tau protein, and the derivative forms are selected from over-phosphorylated forms of the protein, aggregated forms of the protein and modified phosphorylated tau proteins resulting from one or more post-translational modifications; the presence of a marker is detected in a fecal sample of the individual.
Resumen de: AU2024276342A1
Provided herein is a method for diagnosing and treating Alzheimer's disease comprising: (a) providing a biological sample obtained from the subject; (b) measuring concentration levels from the obtained sample, at least one, at least two, at least three, at least four or at least five Alzheimer's-related metabolites described herein and/or at least one, at least two, at least three, at least four or at least five Alzheimer's-related proteins described herein; (c) comparing the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample to the concentration levels of corresponding reference Alzheimer's-related metabolites and/or proteins from an Alzheimer's- negative sample; (d) identifying the subject as having Alzheimer's if the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample are different relative to the concentration levels of the reference Alzheimer's-related metabolites and/or proteins from the Alzheimer's-negative sample; and (e) treating or causing treatment of the subject.
Resumen de: AU2024322991A1
Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ 5 ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.
Resumen de: US20260061081A1
The present disclosure describes formulations, methods, and devices tor biomarker sampling and therapeutic delivery using magnetic formulations. When combined with the application of external magnetic fields, magnetic formulations move within the nasal cavity. Magnetic formulations provide benefits including the ability to: target or steer placement of the formulations via a magnetic field, enhance mixing of the formulation via a magnetic field, enhance biological material collection via antibody-coated magnetic beads, or enhance sample retrieval via a magnetic-tipped inserter. Example biological materials for collection include proteins, enzymes, neural stem cells, and other biomarkers.
Resumen de: AU2024345495A1
The disclosure pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, the disclosure describes methods of assaying a sample obtained from a subject having or suspected of having a cognitive impairment for one or more proteins selected from: DLL1, VNN2, VAV3, and SUMF1. In certain embodiments, the cognitive impairment is caused by a neurodegenerative disease, such as Alzheimer's disease. The methods further comprise identifying a subject as likely or not likely to respond positively to the plasma exchange therapy. In even further aspects, the disclosure describes methods for treating a cognitive impairment in the subject by a plasma exchange therapy, wherein based on the specific protein expression data, the subject is identified as likely or not likely to respond positively to the plasma exchange therapy. The plasma exchange therapy can be full and/or low volume plasma exchange. Also provided are kits suitable for performing the methods disclosed herein.
Resumen de: AU2024325238A1
Material compositions and/or methods useful for the prophylaxis and/or treatment of protein depletion (proteinopenia) are provided, including material compositions that retains native function of a peptide/protein while limiting and/or preventing amyloid formation and/or aggregation of said peptide/protein. Material compositions and formulations for enhancing peptide/protein solubility, stability, circulation time, receptor interaction, brain penetrance, CSF half-life, facilitating peptide/protein synthesis and purification are also provided.
Resumen de: AU2024322991A1
Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ 5 ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.
Resumen de: AU2024277300A1
The present invention relates to compositions and methods for promoting the removal of misfolded proteins and protein aggregates. The compositions and methods may be used to treat or prevent a neurodegenerative disease or disorder associated with misfolded proteins or protein aggregates. In various embodiments, the compositions and methods relate to activators of one or more TRIM proteins.
Resumen de: CN121577904A
本申请公开了一种检测阿尔兹海默病的试纸条及其应用，该试纸条采用胶体金‑辣根过氧化物酶复合物标记技术，通过酶信号放大显著提高了检测灵敏度，可同步检测血液中的两种关键AD生物标志物：p‑Tau‑181和Aβ1‑42。试纸条包括样品垫、标记垫、硝酸纤维素膜及吸水纸，硝酸纤维素膜上设有分别捕获p‑Tau‑181和Aβ1‑42的两条检测线（T1、T2）及一条质控线（C）。具有高灵敏度、快速检测、操作简便、成本低廉，适用于基层医疗和大规模筛查场景，对阿尔兹海默病早期诊断和普及防控具有重要价值。
Resumen de: JP2025137567A
To provide phospho-tau antibodies, and to provide methods of use thereof.SOLUTION: Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays. Provided herein is a method for detecting phosphorylated tau in a sample from an individual comprising: performing an immunoassay on the sample using an antibody or antibody fragment comprising a variable domain, heavy chain region (VH) and a variable domain, light chain region (VL), the VH comprising an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 30 to 34, and the VL comprising an amino acid sequence at least about 90% identical to a sequence as set forth in any one of SEQ ID NOs: 35 to 40.SELECTED DRAWING: None
Resumen de: CN121577908A
本发明公开了一种用于检测汗液中HCG蛋白的复合材料及其制备方法和在AD诊断中的应用，属于生物传感技术领域。该复合材料包括碳纳米管与1T相二硫化钼构成的复合基底材料，以及通过交联剂固定在该基底上的、能够特异性结合HCG蛋白的多肽分子。其制备方法包括采用一锅法溶剂热反应合成CNTs/1T‑MoS₂复合基底，对其进行羧基化修饰，然后与多肽分子偶联。本发明还将该材料固定于工作电极表面，制成传感器，并可集成于微流控芯片形成可穿戴检测贴片。该复合材料与传感器对AD汗液标志物HCG蛋白具有超高灵敏度（检测限达0.45 pg/mL）和特异性，实现了AD的无创、便捷早期诊断，显著提高了患者接受度。
Resumen de: WO2026044141A1
Provided are recombinant diagnostic and therapeutic molecules and methods for their use in detecting and targeting Bcl-2 family proteins and/or Bcl-2 binding partners that are expressed on the surface of a cell or extracellular vesicle (EV) associated with the cancer, disease, or other condition.
Resumen de: WO2026044151A1
Provided are recombinant diagnostic and therapeutic molecules and methods for their use in detecting and targeting Bcl-2 family proteins and/or Bcl-2 binding partners that are expressed on the surface of a cell or extracellular vesicle (EV) associated with the cancer, disease, or other condition.
Resumen de: WO2026044051A1
CD9 expressing microglia are observed in various human neurodegenerative diseases beyond traumatic brain injuries, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. CD9 blocking and FcγRIII blocking methods can be widely used as an intervention strategy to prevent disease-associated cognitive impairment. Therefore, disclosed herein are methods for treating a traumatic brain injury in a subject in need thereof that involve the step of administering to the subject a therapeutically effective amount of a composition comprising an anti-CD9 or an anti FcγRIII blocking agent, such as a blocking antibody.
Resumen de: WO2024220662A2
This document relates to methods and materials for detecting the presence or absence of misfolded polypeptides in a sample. For example, a sample (e.g., a biological sample or an environmental sample) can be exposed to nanoparticles (e.g., nanoparticles having a size of no more than 2 μm (e.g., no more than 1 μm) such as silica nanoparticles (siNPs) having a size of no more than 2 μm (e.g., siNPs having a size of no more than 1 μm)) during a seeded amplification assay to accelerate the aggregation of misfolded polypeptides present in the sample into fibrils and/or polypeptide aggregates (e.g., globular polypeptide aggregates). In some cases, methods and materials provided herein can be used to determine if a mammal (e.g., a human) has a proteinopathy based, at least in part, in the presence or absence of misfolded polypeptides in a sample obtained from the mammal.
Resumen de: CN121554563A
本发明公开了一种蛋白连接酶介导的特异性修饰多肽的合成方法，属于生物工程技术领域。本发明解决了现有技术中磷酸化Tau蛋白难以大规模生产的问题，通过使用Tau多肽来替代全长位点特异性磷酸化Tau蛋白用作临床诊断试剂盒中阳性标品，利用蛋白连接酶催化，实现分段合成含有磷酸化特异性修饰多肽，可将不同来源的多肽在温和条件下高效、定向地连接起来，从而获得结构完整、功能多样的目标蛋白或多肽分子，有效提高肽键合成生产效率。
Resumen de: CN121559086A
本发明属于分子检测技术领域，提供一种双重检测NFL和NFH蛋白的单分子免疫法试剂盒。本发明提供的试剂盒包括固定特异性捕获抗体的固相载体、识别不同表位且标记可区分信号标记物的检测抗体，及洗涤液、封闭液、校准品、质控品，通过夹心免疫反应结合单分子检测技术，能够同步检测样品中NFL和NFH的含量。本发明提供的试剂盒，检测灵敏度可达fg/mL级别，且特异性强、操作简便，无需创伤性脑脊液采集，适用于神经退行性疾病的早期诊断、病情监测及疗效评估。
Resumen de: CN121559077A
本发明公开了基于荧光探针的ATP水解酶抗体高效筛选法，包括生化体系和细胞体系两种检测方案，在生化体系中，通过定量ENTPD2蛋白水解ATP后剩余量，直接计算抗体抑制率；在细胞体系中，利用过表达ENTPD2的细胞验证抗体对跨膜酶的抑制功能。该生化体系方法无需抗体纯化，仅需5-15μL B细胞上清液即可完成初筛，筛选准确度高(细胞体系可用作验证筛选得到的抗体)，与体内药效结果一致，适用于抗ENTPD2抗体药物的开发，显著降低研发成本。
Resumen de: KR20260024607A
본 발명은 아밀로이드 베타(amyloid beta, Aβ)와 특이적으로 결합하는 클러스터린(clusterin) 펩타이드 및 이의 용도에 관한 것이다. 본 발명의 아밀로이드 베타(Aβ)의 특이적으로 결합하는 클러스터린 유래 폴리펩타이드를 이용하는 경우, 아밀로이드 베타의 섬유화 및 올리고머화를 방지할 수 있으므로, 아밀로이드 베타 관련 퇴행성 신경질환의 치료 및 예방에 사용할 수 있으며, 뿐만 아니라, 클러스터린 베타 서브유닛(clusterin-β subunit)은 아밀로이드 베타 관련 퇴행성 신경질환의 진단을 위한 바이오마커로서 활용될 수 있다.
Resumen de: US20260048090A1
The present disclosure relates to an engineered M13 bacteriophage displaying amyloidogenic peptide motifs from amyloid beta 42 (Aβ42) at its surface. The present disclosure further relates to the use of the disclosed engineered M13 bacteriophage for detecting early species of Aβ, namely oligomeric and fibrillar Aβ, and preventing its aggregation promoting the inhibition of the progression of Alzheimer's disease and thus contributing to the treatment of this neurodegenerative disorder.
Resumen de: AU2026200694A1
Methods of measuring the amount of singly- or multiply-phosphorylated p217+ tau protein in a sample are provided. Methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of a treatment of a tauopathy, and methods of determining whether a subject is suitable for anti-p217+ tau antibody therapy are also provided. Also described are antibodies for use in the methods and kits comprising the antibodies. an a n
Resumen de: WO2026039416A1
Described herein are detecting methods for conformational disease, aging and proteinopathies, by measuring the presence of b-isox-precipitates and the levels of b-isox-captured proteins in biofluids of healthy individuals and patients. Research identified additional biomarkers, which made it possible to detect, diagnose or treat, a human disease in a human subject by, with or without adding an isoxazole to an obtained biofluid sample, detecting the biomarker. Use of b-iso and/or biomarkers for diagnosing the disease are made possible.
Resumen de: US20260048083A1
A method for treating Alzheimer's disease is disclosed. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). A composition for treating Alzheimer's disease is also disclosed.
Resumen de: EP4697021A2
An embodiment according to the present invention provides a kit or device for detection of dementia, and a method for detecting dementia. An embodiment according to the present invention relates to: a kit or device for detection of dementia, including a nucleic acid(s) capable of specifically binding to an miRNA(s) or a complementary strand(s) thereof in a sample from a subject; and a method for detecting dementia, including measuring the miRNA(s) in vitro.
Resumen de: AU2024249796A1
The present invention relates to protein markers relevant to mild cognitive impairment (MCI) and Alzheimer's disease (AD), especially those detectable in blood samples. Thus, methods and compositions are provided for risk assessment and early diagnosis of MCI and AD based on the analysis of these protein markers. Further provided are methods and compositions useful for evaluating the efficacy of a therapy for MCI or AD.
Resumen de: CN121540882A
本发明公开了磷酸化Tau蛋白和磁珠的偶联物及其制备方法和试剂盒，涉及免疫分析技术领域。本申请通过将修饰有叠氮基团的改性磁珠和修饰有DBCO基团的改性抗磷酸化Tau蛋白的抗体通过点击化学的方式高效、定向偶联，相比传统物理吸附或非特异性化学偶联方法，具有偶联效率高、结合稳定性强、抗体活性保留率高等优势，可显著提升磁珠对血液中低丰度p‑Tau的捕获效率和特异性，检测下限低至0.3 pg/mL以下，在早期AD的诊断中展现出卓越的准确性，能够精准识别早期AD患者血液中p‑Tau的细微变化，为AD的早期筛查、病程监测及干预效果评估提供了可靠的工具。
Resumen de: CN120187864A
The present invention relates to neurodegenerative diseases, and to the diagnosis and/or prognosis of neurodegenerative diseases in test subjects using lateral flow testing or the like. The invention also relates to the detection of diagnostic and prognostic biomarkers in a variety of patient sample types for the diagnosis and/or prognosis of neurodegenerative diseases, such as Alzheimer's disease. The invention also provides biomarker detection methods and devices for diagnosis and prognosis of neurodegenerative diseases and methods of treating patients diagnosed or prognosed with neurodegenerative diseases. The invention also extends to detection of biomarkers and/or screening in subjects before symptoms for early diagnosis, so that diseases can be prevented or intervened.
Resumen de: WO2024166074A1
The present invention relates to a method of isolating exosomes from human immature dental pulp stem cell (hIDPSC) cultures that is scalable. The present invention also provides pharmaceutical compositions comprising exosomes and methods of using these pharmaceutical compositions to treat a neurological disease or condition, infectious disease, or cancer.
Resumen de: CN121522171A
本发明公开了一种多重级联放大的超灵敏化学发光试剂盒及其应用，属于试剂盒技术领域，该试剂盒包括链霉亲和素包被的磁性微粒试剂、生物素‑链霉亲和素桥接复合物试剂和吖啶酯标记的检测抗体试剂；链霉亲和素包被的磁性微粒试剂是以超顺磁微粒为起始物，以生物素衍生物为桥联剂，通过生物素衍生物与链霉亲和素交替、逐层偶联制备而成，其最外层为链霉亲和素；生物素‑链霉亲和素桥接复合物试剂是捕获抗体为起始物，以链霉亲和素为桥联剂，通过链霉亲和素和生物素衍生物交替、逐层偶联制备而成，其最外层为生物素衍生物，本发明试剂盒适用于如阿尔茨海默病早期诊断或细胞因子风暴等低丰度疾病标志物的体外检测。
Resumen de: US20260043815A1
Described herein are detecting methods for conformational disease, aging and proteinopathies, by measuring the presence of b-isox-precipitates and the levels of b-isox-captured proteins in biofluids of healthy individuals and patients. Research identified additional biomarkers, which made it possible to detect, diagnose or treat, a human disease in a human subject by, with or without adding an isoxazole to an obtained biofluid sample, detecting the biomarker. Use of b-iso and/or biomarkers for diagnosing the disease are made possible.
Resumen de: US20260043816A1
TDP-43 binding molecules specifically binding phosphorylated TDP-43 are provided, together with the nucleic acid molecules that encode the binding molecules. These binding molecules are useful in diagnostic and therapeutic applications and may be included in suitable compositions and kits. They may be used in pairing assays involving use of capture and detect antibody pairs. They may be used to monitor diseases associated with TDP-43, including for testing candidate therapeutic agents.
Resumen de: US20260043791A1
A kit for diagnosing Alzheimer's disease and a pharmaceutical composition for treating Alzheimer's disease are disclosed, in which EDIL3 or a nucleic acid encoding EDIL3 is used as an index or target.
Resumen de: WO2026035942A1
The present invention provides novel compositions and methods for treating diseases and conditions associated with amyloid beta in a subject, said method comprising administering to the subject (i) an anti-amyloid beta antibody or an antigen binding fragment thereof and (ii) a regulatory T cell (Treg) inducing or activating agent.
Resumen de: WO2026033422A1
Provided herein is a method of identifying a pre-stage neurofibrillary tangle (NFT) in a patient sample, including obtaining a sample from a patient suspected of having or at risk of developing a tauopathy, incubating the sample with a composition comprising a first binding reagent, wherein the first binding reagent is specific to Ser262 and/or Ser356 of a tau protein, and detecting binding between the first binding reagent and the tau protein, wherein detecting binding between the first binding reagent and the tau protein indicates the presence of a pre-stage NFT in the patient sample.
Resumen de: KR20260020793A
본 발명은 치매 또는 경도인지장애 진단용 바이오마커에 관한 것으로, 더욱 상세하게는 개체의 수득된 시료에서 특정 아실카르니틴 조합의 수준을 측정함으로써 치매 또는 경도인지장애를 조기 진단하는 조성물, 이를 포함하는 치매 또는 경도인지장애 진단용 키트, 및 치매 또는 경도인지장애 진단 방법에 관한 것이다.
Resumen de: CN121496001A
本发明涉及包含Plaur基因的载体及其在神经损伤相关疾病中的应用。本发明证实通过AAV病毒载体增强Plaur基因的表达，能够显著增强神经元轴突再生能力，并提高神经再生的效率。这一效果在视神经损伤模型中得到了验证。本申请为神经保护和神经再生提供了新的靶点，为神经再生提供了基因治疗的手段，还为神经损伤相关疾病的治疗开辟了新的途径。
Resumen de: AU2024291458A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD, based on presence of antimicrobial peptides (AMPs) at levels that differ from those in control individuals.
Resumen de: CN121476586A
本发明提供了一种基于动态偶联与信号增强的化学发光免疫检测试剂盒，包括协同作用的pH响应动态偶联组件、多模态抗干扰组件和FRET延时发光探针，三者通过“偶联‑反应‑信号”的时序适配形成闭环检测系统；还包括抗原标准品，稀释液和激发液。通过pH响应动态偶联组件实现抗体可逆固定与循环利用，多模态抗干扰组件解决复杂基质干扰问题，FRET延时发光探针提升信号检测能力，三者协同作用显著改善免疫检测性能，具有高灵敏、高特异性、抗干扰的特点。
Resumen de: AU2024291458A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD, based on presence of antimicrobial peptides (AMPs) at levels that differ from those in control individuals.
Resumen de: US20260034143A1
Compositions of Allopregnanolone (Allo), and methods of use thereof for treating and preventing Alzheimer's Disease (AD) or dementia have been developed. In some embodiments, the amount of Allo effective to treat AD or dementia is between about 2 mg and about 10 mg, preferably 4 mg per dose. Methods for identifying subjects for treatment of AD or dementia are also provided. The methods include selecting a subject having one or more Apo E4 gene alleles. Methods of treating a human subject having AD or at risk of AD OR DEMENTIA are provided. The methods include administering a dosage of from 2 mg to 6 mg to the subject once within a 24 hour period. The dosing is repeated every seven days, or less frequently. The methods stimulate mitosis of neural progenitor cells, stimulate neurite growth and organization, protect against neural loss, or one or more of these neural processes.
Resumen de: WO2026027796A1
The present invention relates to peptides, in particular of amyloid inhibitory peptides, and to pharmaceutical compositions comprising such peptides, for use in methods of treating or preventing or delaying the onset of synucleinopathies, in particular of Parkinson's disease (PD) or dementia with Lewy bodies, and their comorbidities, in particular PD/type 2 diabetes (T2D) and PD/Alzheimer's disease (AD). Furthermore, the present invention relates to such peptides, in particular such amyloid inhibitory peptides, for use in methods of diagnosing such synucleinopathies and related comorbidities. Furthermore, the present invention also relates to a kit for the in-vitro or in-vivo detection and, optionally, quantification of amyloidogenic polypeptides, amyloid fibrils or amyloid aggregates, and/or for the diagnosis of synucleinopathies and related comorbidities, in particular PD/type 2 diabetes (T2D) and PD/Alzheimer's disease (AD), in a patient.
Resumen de: US20260035756A1
The present invention relates to methods and kits for the collection, preservation and storage of analytes of interest present in biological test samples (biofluid samples). In particular, the present invention relates to means to collect the biological test sample such that substantially all pathogen present in the biological test sample is inactivated, while preserving the analyte of interest in a format to allow subsequent analysis.
Resumen de: US20260034088A1
Provided herein is the use of a compound of Formula I:or a pharmaceutically acceptable salt thereof, for treating a disease characterized by amyloid and amyloid-like aggregates, e.g., Alzheimer's disease.
Resumen de: WO2026030628A2
Methods for target, biomarker, and patient selection discovery in central nervous system disorders utilizing patient-derived cellular models, spatial proteomics, and machine learning. The method generates neural cells from forebrain regions from induced pluripotent stem cells, performs cell-type specific proteome profiling using antibody-enzyme conjugates and spatial proteome profiling, and applies statistical data augmentation to sparse biological datasets. Machine learning classifiers with SHAP-based feature importance identify ranked biomarkers from mass spectrometry data. The platform enables patient stratification by linking molecular signatures to symptom severity, drug screening through biomarker modulation, and diagnostic applications. Kits comprising antibodies for biomarkers including antibodies for biomarkers identified by the method facilitate implementation. Applications include autism spectrum disorder, rare neurodevelopmental disorders, schizophrenia, epilepsy, Alzheimer's disease, and Parkinson's disease.
Resumen de: EP4686725A1
The present invention relates to peptides, in particular of amyloid inhibitory peptides, and to pharmaceutical compositions comprising such peptides, for use in methods of treating or preventing or delaying the onset of synucleinopathies, in particular of Parkinson's disease (PD) or dementia with Lewy bodies, and their comorbidities, in particular PD/type 2 diabetes (T2D) and PD/Alzheimer's disease (AD). Furthermore, the present invention relates to such peptides, in particular such amyloid inhibitory peptides, for use in methods of diagnosing such synucleinopathies and related comorbidities. Furthermore, the present invention also relates to a kit for the in-vitro or in-vivo detection and, optionally, quantification of amyloidogenic polypeptides, amyloid fibrils or amyloid aggregates, and/or for the diagnosis of synucleinopathies and related comorbidities, in particular PD/type 2 diabetes (T2D) and PD/Alzheimer's disease (AD), in a patient.
Resumen de: CN120457337A
The present disclosure provides a method of preparing a biosensor for detecting Alzheimer's disease biomarkers, comprising depositing an alumina film on a Si substrate by an atomic layer deposition system to form an Al2O3/Si substrate; depositing an electric contact part Cr/Au on the Al2O3/Si substrate through a thermal evaporator, and forming a source electrode, a drain electrode and a planar grid electrode on the Al2O3/Si substrate; providing double-layer graphene on the Al2O3/Si substrate through thermal annealing in a vacuum environment; performing low-damage plasma treatment (LDPT) on the double-layer graphene with a mixture of oxygen and hydrogen to form a graphene oxide/graphene (GO/G) layered composite material on the Al2O3/Si substrate; an antibody is immobilized on the surface of a GO/G layered composite material by a reaction between an amine group of the antibody and a carboxyl group of GO of the GO/G layered composite material, where the antibody is specific for p-tau217 protein.
Resumen de: JP2025118826A
To provide methods and compositions useful for diagnosis of AD, as well as methods and compositions useful for indicating therapeutic efficacy of an agent for treating AD.SOLUTION: A method for determining whether a subject has an increased risk of subsequently developing AD is provided, the method comprising: (1) comparing the subject's plasma, serum, or whole blood level or concentration of any one protein selected from Tables 1-4 with a standard control level of the same protein found in the plasma, serum, or whole blood of an average healthy subject not suffering from or at increased risk for AD; (2) detecting that the subject's plasma, serum, or whole blood level of the protein having a positive β value or a negative β value in Table 1, 2, 3, or 4 is higher or lower than the standard control level; and (3) determining that the subject has an increased risk for AD.SELECTED DRAWING: Figure 1
Resumen de: CN121453876A
本发明公开了基于TdT‑Cas12a反应体系和HaeⅢ酶的电化学生物传感器及阿尔茨海默生物标志物检测方法，电化学生物传感器包括TdT反应体系以及Cas12a反应体系，所述TdT反应体系包括TdT酶、TdT缓冲液、脱氧腺嘌呤三磷酸(dATP)以及标志物核酸转化产物，反应得到TdT延伸产物；所述Cas12a反应体系包括反应缓冲液、Cas12a蛋白、crRNA和TdT延伸产物，在孵育后得到Cas12a体系产物；电化学生物传感器的构建方法为：在金电极表面结合生物探针P，完成电极表面修饰；将Cas12a体系产物加入金电极表面，继续孵育。本发明的电化学生物传感器具有优异的灵敏度和特异性，可显著提高NDE中AD相关蛋白的检测灵敏度，可用于人血清样品的分析，回收率高。
Nº publicación: IL325709A 01/02/2026
Solicitante:
F HOFFMANN LA ROCHE AG [CH]
FRESKGARD PER OLA [CH]
GEORGES GUY [DE]
IMHOF JUNG SABINE [DE]
NEUBAUER MARKUS [DE]
NIEWOEHNER JENS [DE]
RUEGER PETRA [DE]
F. HOFFMANN-LA ROCHE AG,
FRESKGARD Per-Ola,
GEORGES Guy,
IMHOF-JUNG Sabine,
NEUBAUER Markus,
NIEWOEHNER Jens,
RUEGER Petra
Resumen de: AU2024322991A1
Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ 5 ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.
BOPI
Sede Electrónica
